By focusing on key, early, driving mutations, an exciting possibility is that more advanced versions of the DEABM could help identify novel chemopreventive targets in the specific pathways leading to ER+ and ER—invasive breast cancers. Here, ESR1 is linked to invasive breast carcinoma.